| |
| |
|
| Insider
Information: |
Yanover Paul |
| Relationship: |
Director |
| City: |
Los Angeles |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
1,163 |
|
|
Indirect Shares
|
4,100 |
|
|
| Direct
Value |
$2,326 |
|
|
|
Indirect Value
|
$8,200 |
|
|
| Total
Shares |
5,263 |
|
|
| Total
Value |
$10,526 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Eterna Therapeutics Inc |
ERNA |
Director |
2017-09-29 |
1,163 |
2017-09-29 |
4,100 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
4 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ERNA |
Eterna Therapeutics Inc |
Director |
– • – |
2017-09-29 |
4 |
A |
$0.00 |
$0 |
D/D |
612 |
1,163 |
0 |
- |
|
| ERNA |
Eterna Therapeutics Inc |
Director |
– • – |
2016-05-26 |
4 |
B |
$0.15 |
$10,898 |
I/I |
65,000 |
205,000 |
2.1 |
- |
|
| ERNA |
Eterna Therapeutics Inc |
Director |
– • – |
2015-06-19 |
4 |
B |
$0.25 |
$9,964 |
I/I |
40,000 |
140,000 |
2.1 |
- |
|
| ERNA |
Eterna Therapeutics Inc |
Director |
– • – |
2012-12-14 |
4 |
GA |
$0.00 |
$0 |
D/D |
100,000 |
100,000 |
0 |
- |
|
4 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
